Long-term outcomes of interventional treatment for Budd–Chiari syndrome with chronic accessory hepatic vein obstruction

Li, Huawei; Zhang, Xi; Xu, Hao; Zu, Maoheng; Wei, Ning; Liu, Hongtao; Xiao, Jinchang; Shen, Bin; Huang, Qianxin; Zhang, Qingqiao

doi:10.1097/meg.0000000000001784

Cited by 2 publications

(2 citation statements)

References 31 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on findings from seven studies [ 13 – 16 , 18 – 21 ], pooled AHV pressure decreased significantly after recanalization relative to pre-procedure levels (MD: 19.85; 95% CI: 15.56–24.14, P < 0.00001, Fig. 2 b).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Lv,

Xu,

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

Background Budd-Chiari syndrome (BCS) results when the outflow of the hepatic vein (HV) is obstructed. BCS patients exhibiting an accessory HV (AHV) that is dilated but obstructed can achieve significant alleviation of liver congestion after undergoing AHV recanalization. This meta-analysis was developed to explore the clinical efficacy of AHV recanalization in patients with BCS. Materials and methods PubMed, Embase, and Wanfang databases were searched for relevant studies published as of November 2022, and RevMan 5.3 and Stata 12.0 were used for pooled endpoint analyses. Results Twelve total studies were identified for analysis. Pooled primary clinical success, re-stenosis, 1- and 5-year primary patency, 1- and 5-year secondary patency, 1-year overall survival (OS), and 5-year OS rates of patients in these studies following AHV recanalization were 96%, 17%, 91%, 75%, 98%, 91%, 97%, and 96%, respectively. Patients also exhibited a significant reduction in AHV pressure after recanalization relative to preoperative levels (P < 0.00001). Endpoints exhibiting significant heterogeneity among these studies included, AHV pressure (I2 = 95%), 1-year primary patency (I2 = 51.2%), and 5-year primary patency (I2 = 62.4%). Relative to HV recanalization, AHV recanalization was related to a lower rate of re-stenosis (P = 0.002) and longer primary patency (P < 0.00001), but was not associated with any improvements in clinical success (P = 0.88) or OS (P = 0.29) relative to HV recanalization. Conclusions The present meta-analysis highlights AHV recanalization as an effective means of achieving positive long-term outcomes in patients affected by BCS, potentially achieving better long-term results than those associated with HV recanalization.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Based on the results of five studies [ 11 , 15 , 16 , 19 , 22 ], the pooled 5-year OS rate was 95% (95% CI: 92%-98%, Fig. 2 i).…”

Section: Resultsmentioning

confidence: 99%

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Lv,

Xu,

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Budd-Chiari syndrome (BCS) results when the outflow of the hepatic vein (HV) is obstructed. BCS patients exhibiting an accessory HV (AHV) that is dilated but obstructed can achieve significant alleviation of liver congestion after undergoing AHV recanalization. This meta-analysis was developed to explore the clinical efficacy of AHV recanalization in patients with BCS. Materials and Methods PubMed, Embase, and Wanfang databases were searched for relevant studies published as of November 2022, and RevMan 5.3 and Stata 12.0 were used for pooled endpoint analyses. Results Twelve total studies were identified for analysis. Pooled primary clinical success, re-stenosis, 1- and 5-year primary patency, 1- and 5-year secondary patency, 1-year overall survival (OS), and 5-year OS rates of patients in these studies following AHV recanalization were 96%, 17%, 91%, 75%, 98%, 91%, 97%, and 96%, respectively. Patients also exhibited a significant reduction in AHV pressure after recanalization relative to preoperative levels (P < 0.00001). Endpoints exhibiting significant heterogeneity among these studies included, AHV pressure (I2 = 95%), 1-year primary patency (I2 = 51.2%), and 5-year primary patency (I2 = 62.4%). Relative to HC recanalization, AHV recanalization was related to a lower rate of re-stenosis (P = 0.002) and longer primary patency (P < 0.00001), but was not associated with any improvements in clinical success (P = 0.88) or OS (P = 0.29) relative to HV recanalization. Conclusions The present meta-analysis highlights AHV recanalization as an effective means of achieving positive long-term outcomes in patients affected by BCS, potentially achieving better long-term results than those associated with HV recanalization.

show abstract

Long-term outcomes of interventional treatment for Budd–Chiari syndrome with chronic accessory hepatic vein obstruction

Cited by 2 publications

References 31 publications

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Contact Info

Product

Resources

About